Takeda Pharmaceutical Co.'s experimental dengue vaccine was highly effective at preventing the mosquito-borne disease in a late stage study, but it failed to protect against one type of the virus in people with no prior exposure to dengue.
Takeda's vaccine was 80.2 percent effective at preventing dengue among children and teens in the year after they got the shot, according to results of a Phase III study published in the New England Journal of Medicine on Wednesday.
Sanofi's Dengvaxia — the world's first dengue vaccine — had demonstrated 59.2 percent overall efficacy in the first year of follow-up based on combined results from two late stage trials.